Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
NCT02944448 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
- Lead sponsor
- Cara Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- June 30, 2017
- Enrollment
- 761 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.